QPEX BIOPHARMA is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.
Qpex management has a record of deep expertise in the discovery, development, and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance.
Untreatable infections due to antimicrobial drug resistance negates many advances in medical technology
The year 2019 marks the 50th anniversary of the publication of the landmark science fiction novel The Andromeda Strain (Michael Crichton). The story describes the fictitious account of a highly mutable micro-organism that infects and kills humans, escapes containment, and threatens mankind.
The story behind the Andromeda Strain makes for great novels and films on the horrors of a battle between man and unseen micro-organisms. In our “real world”, we are now challenged by antimicrobial drug resistance (also known as AMR), common bacterial pathogens no longer are treatable by antibiotic drugs. Infections that were once considered mild and easily treated can become life threatening in the absence of active antibiotics.
AMR results in a world where the advances in modern medicine are lost...
Reversing antibiotic resistance
Executive Chairman of the Board
Carol Gallagher, PharmD
New Enterprise Associates,
Kevin Li, PhD
LYZZ Capital, Board Member
Michael N. Dudley, PharmD
President, CEO, Board Member
Adams Street Partners, Board Member
Douglas Reed, MD
Hatteras Venture Partners, Board Member